Comparing Ovarian Clear Cell Carcinoma and High-Grade Serous Carcinoma Based on the SEER Database and Analyzing the Significantly Mutated Genes

The independent prognostic factors identified in this study provide a theoretical basis for individualized prognosis judgment in OCCC and HGSC. The SMGs and TMB levels may serve as valuable indicators for prognosis and evaluating targeted therapy or immunother-apy efficacy. Druggable genes such as NOTCH1 and RYR3 offer promising therapeutic tar-gets, while stage-specific pathway enrichments reveal potential intervention strategies. Further validation in larger cohorts is needed to confirm these findings. Our study advances the under-standing of molecular heterogeneity in ovarian cancer and lays the groundwork for personal-ized treatment strategies, ultimately improving patient outcomes.

Authors

Institutions

Publication Details

Journal
Current Cancer Drug Targets
Published
2025-08-28
DOI
https://doi.org/10.2174/0115680096370568250806153217
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparing Ovarian Clear Cell Carcinoma and High-Grade Serous Carcinoma Based on the SEER Database and Analyzing the Significantly Mutated Genes

Haijing He, Jiangtao Fan, Shiyu Zhang, Yuqi Wen et al.
Current Cancer Drug Targets
RNA modifications and cancer
article

Comparing Ovarian Clear Cell Carcinoma and High-Grade Serous Carcinoma Based on the SEER Database and Analyzing the Significantly Mutated Genes

Haijing He, Jiangtao Fan, Shiyu Zhang, Yuqi Wen, Ying Yang, Xuzhi Liang
article en

Abstract

The independent prognostic factors identified in this study provide a theoretical basis for individualized prognosis judgment in OCCC and HGSC. The SMGs and TMB levels may serve as valuable indicators for prognosis and evaluating targeted therapy or immunother-apy efficacy. Druggable genes such as NOTCH1 and RYR3 offer promising therapeutic tar-gets, while stage-specific pathway enrichments reveal potential intervention strategies. Further validation in larger cohorts is needed to confirm these findings. Our study advances the under-standing of molecular heterogeneity in ovarian cancer and lays the groundwork for personal-ized treatment strategies, ultimately improving patient outcomes.

Current Cancer Drug TargetsVol. 25
Guangxi Medical University (CN), First Affiliated Hospital of GuangXi Medical University (CN)
Openalex Percentile: Top 80%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.